Neuroendocrine tumors: general characteristics and features of management tactics


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Neuroendocrine tumors (NETs) - a group of rare tumors that can develop in any organs, have their own unique characteristics of origin, course and diagnosis. The development of visual, immunohistochemical diagnostic methods, the identification of the main biochemical markers contributed to an increase in the NETs detection in the world. The choice of treatment option depends on the location, extent of the process and the functional status of the tumor.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Alexander Kuzminov

N.N. Blokhin National Medical Research Center of Oncology

Email: alexkouzminov@mail.ru
PhD in Medical Sciences, Researcher

V. Gorbunova

N.N. Blokhin National Medical Research Center of Oncology

Әдебиет тізімі

  1. Modlin I.M., Champaneria M.C., Chan A.K.C., Kidd M. A three-decade analysis of 3,911 small intestinal neuroen-docrine tumors: the rapid pace of no progress. Am. J. Gastroenterol. 2007;102(7):1464-73.
  2. Strosberg J.R., Nasir A., Hodul P., Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008;2(3):113-25.
  3. Berge T., Linell F. Carcinoid tumours. Fre-quency in a defined population during a 12-year period. Acta Pathol MicrobiolScand. 1976;84(4):322-30.
  4. Kaltsas G.A., Besser G.M., Grossman A.B. The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocrin. Rev. 2004;25(3):458511.
  5. Sorbye H., Welin S., Langer S.W., et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol, 2013;24(1):152-60.
  6. Garcia-Carbonero R., Capdevila J., Crespo-Herrero G., et al. Incidence, patternsofcare andprognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol, 2010;21(9):1794-803.
  7. Sorbye H., Strosberg J., Baudin E., et al. Gastroenteropancreatic high-gradeneuroendocrine carcinoma. Cancer. 2014;120(18):2814-23. doi: 10.1002/cncr.28721.
  8. Rindi G., Falconi M., Klersy C., et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J. Natl. Cancer Inst. 2012;104(10):764-77.
  9. Korse C.M., Taal B.G., Vincent A., et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur. J. Cancer. 2012;48(5):662-71. Doi: 10.1016/j. ejca.2011.08.012.
  10. Baudin E., Gigliotti A., Ducreux M., et al. Neuron specific enolase and chromogranin A as markers of neuroendocrine tumours. Br. J. Cancer, 1998;78(8):1102.
  11. Brenner B., et al. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol. 2007;34(1):43-50. Doi: 10.1053/j. seminoncol.2006.10.022
  12. Sorbye H., Westre B., Horn A. Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. Eur. J. Surg. Oncol. (EJSO). 2007;33(10):1209-10.
  13. Yamaguchi T, Machida N., Morizane C., et al. Muiticenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sei. 2014;105(9):1176-81. Doi: 10.1111/ cas.12473.
  14. Moertei C.G., Kvois L.K., O'Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2):227-32.
  15. Mitry E., Baudin E., Ducreux M., et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer. 1999;81(8):1351. Doi: 10.1038/ sj.bjc.6690325
  16. Iwasa S., Morizane C., Okusaka T., et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jap. J. Clin. Oncol. 2010;40(4):313-18. doi: 10.1093/jjco/ hyp173.
  17. Deutschbein T., Unger N., Yuece A., et al. Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a singlecenter experience. Hormone and metabolic research Hormon-und Stoffwechselforschung. Hormon. Metabol. 2011 ;43(12):838-43. doi: 10.1055/s-0031-1284354.
  18. Patta A., Fakih M. First-line cisplatin plus etoposide in high- grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res. 2011;31(3):975-78.
  19. Munhoz R.R., et al. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors. 2013;5(3):e39-e39. DO!: 10.4081/ rt.2013.e39.
  20. Okita N.T., Kato K., Takahari D., et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric. Cancer. 2011;14(2):161-65.
  21. Nakano K., Takahashi S., Yuasa T., et al. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jap. J. Clin. Oncol. 2012;42(8):697-703.
  22. Okuma H.S., et al. Irinotecan plus Cisplatin in Patients with Extensive-Disease Poorly Differentiated Neuroendocrine Carcinoma of the Esophagus. Anticancer Res. 2014;34(9): 5037-41.
  23. Lu Z., Li J., Lu M., et al. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas. Med. Oncol. 2013;30(3):1-5.
  24. Kulke M.H., Stuart K., Enzinger P.C., et al. A phase !! trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Digest. Dis. Sci. 2006;51(6):1033-38.
  25. Welin S., Sorbye H., Sebjornsen S., et al. Clinical effect of temozolomide- based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy Cancer. 2011;117(20):4617-22. Doi: 10.1002/ cncr.26124.
  26. Ezziddin S., Opitz M., Attassi M., et al. Impact of the Ki- 67 proliferation index on response to peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. !mag. 2011;38(3):459-66.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2018

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>